MSTN抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P03981(MSTN Antibody) at dilution 1/8. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P03981(MSTN Antibody) at dilution 1/8. (Original magnification: ×200)    

  
  

The myostatin (MSTN) antibody is a therapeutic or research tool targeting myostatin, a protein encoded by the MSTN gene and a member of the TGF-β superfamily. Myostatin acts as a negative regulator of skeletal muscle growth by inhibiting muscle cell proliferation and differentiation. Discovered in 1997. MSTN gained attention when genetic knockout in animals (e.g., "mighty mice" or hypermuscular cattle) resulted in dramatic muscle hypertrophy. This discovery spurred interest in modulating MSTN to treat muscle-wasting disorders like muscular dystrophy, sarcopenia, and cachexia.

MSTN antibodies work by binding to circulating myostatin, blocking its interaction with cell surface receptors (e.g., activin type IIB receptor), thereby neutralizing its inhibitory effects on muscle development. Preclinical studies in animal models demonstrated increased muscle mass and strength, leading to clinical trials for conditions such as Duchenne muscular dystrophy (DMD). Notable candidates include domagrozumab and stamulumab, though mixed efficacy outcomes have prompted ongoing optimization.

Beyond therapeutics, MSTN antibodies are used in agriculture to enhance livestock lean meat yield. Challenges include balancing muscle growth with potential off-target effects and long-term safety. Research continues to explore combinatorial approaches, such as pairing MSTN inhibition with other anabolic pathways, to maximize therapeutic benefits while minimizing risks.